Signal Explorer
10-K · 10-Q · 8-K · last 6 months · ← back to feed
Aquestive Therapeutics, Inc.
AQST
Other
Director Officer Indemnification Provision
Stock Certificate Signature Requirement
Equity Plan Board Approval Conditional On Shareholder Vote
President Duties Defined
Other
Priority Review Or Pdufa Disclosed
Safety Differentiated
Core
Indication Expansion
Near Term Regulatory Decision
Biotech Risk
Crl Received
Core
Regulatory Designation Only
Indication Expansion
Near Term Regulatory Decision
Other
Fast Track Designation Received
Patent Family Portfolio Disclosure
Fast Track Granted
Orphan Status Granted
Breakthrough Therapy Granted
Priority Review Or Pdufa Disclosed
Rmat Designation Received
Biotech Risk
Orphan Drug Designation
Other
Classified Board Director Election
Board Diversity Policy Disclosed
Executive Transition Gratitude Statement
Biotech Risk
Crl Received
Core
Clinical Trial Result
Other
Safety Differentiated
Patient Retention High
Interim Data Positive
Other
Ceo Team Pride Statement
Interim Data Positive
Board Committee Member Listing
Core
Clinical Trial Result
Indication Expansion
Secondary Endpoint Mentioned
Biotech Risk
Crl Received
Trial Endpoint Missed
Accelerated Approval
Other
Tenant Restoration Obligation
Operating Lease Rent Expense Disclosed
Liquidity Position Snapshot Disclosed
Warrant Valued Black Scholes
Use Of Proceeds Disclosure
Cash Flow Statement Investing Activities
Corporate Authority Representation
Rsu Psu Vesting Schedule Disclosed
Stock Option Grant Disclosed
Debt Note Interest Terms Disclosed
Amendment Modification Waiver Clause
Credit Agreement Schedule Amendment
Effective Tax Rate Reconciliation
Libor Based Term Loan Pricing
Business Services
Demand Softening
Core
Secondary Endpoint Mentioned
Indication Expansion
Clinical Trial Result
Regulatory Designation Only
Other
Earnings Call Replay Details
Net Loss Reported
Interim Data Positive
Adjusted Ebitda Period Comparison
Liquidity Position Snapshot Disclosed
Fda Aligned
Safety Differentiated
Healthcare
Pricing Power Services
Biotech Risk
Crl Received
Biotech Risk
Crl Received
Core
Clinical Trial Result
Indication Expansion
Other
Kol Endorsement
Patient Retention High
Interim Data Positive
Fda Aligned
Publication Positive
Healthcare
Reimbursement Improving
Other
Auditor Appointment Ratification
Classified Board Director Election
Other
Warrant Valued Black Scholes
Liquidity Position Snapshot Disclosed
Operating Lease Rent Expense Disclosed
Rsu Psu Vesting Schedule Disclosed
Director Officer Indemnification Provision
Effective Tax Rate Reconciliation
Employment Termination Upon Death
Cash Flow Statement Investing Activities
Stock Option Grant Disclosed
Depreciation Expense Composition Disclosure
Revenue Decline Explanation
Confidential Information Return Obligation
Priority Review Or Pdufa Disclosed
Financing Activities Cash Flow Disclosure
Core
Clinical Trial Result
Other
Use Of Proceeds Disclosure
Libor Based Term Loan Pricing
Liquidity Position Snapshot Disclosed
Headcount Disclosure Standard
Net Loss Reported
Personnel Cost Decrease Disclosure
Adjusted Ebitda Period Comparison
Patient Retention High
Ceo Earnings Call Commentary
Interim Data Positive
Administrative Efficiency
Core
Clinical Trial Result
Lead Asset Progress
Healthcare
Pricing Power Services
Biotech Risk
Crl Received